FibroBiologics, Inc. (FBLG)
0.95
-0.07
(-6.86%)
USD |
NASDAQ |
Oct 23, 16:00
0.9643
+0.01
(+1.51%)
After-Hours: 20:00
FibroBiologics Enterprise Value : 3.724M for Oct. 23, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 23, 2026 | 3.724M |
| October 22, 2026 | 4.149M |
| October 21, 2026 | 3.985M |
| October 20, 2026 | 3.540M |
| October 19, 2026 | 3.688M |
| October 16, 2026 | 3.851M |
| October 15, 2026 | 4.028M |
| October 14, 2026 | 3.724M |
| October 13, 2026 | 3.784M |
| October 12, 2026 | 4.028M |
| October 09, 2026 | 4.818M |
| October 08, 2026 | 4.696M |
| October 07, 2026 | 4.879M |
| October 06, 2026 | 4.818M |
| October 05, 2026 | 5.122M |
| October 02, 2026 | 5.487M |
| October 01, 2026 | 5.274M |
| September 30, 2026 | 5.852M |
| September 29, 2026 | 5.913M |
| September 28, 2026 | 6.217M |
| September 25, 2026 | 6.399M |
| September 24, 2026 | 6.217M |
| September 23, 2026 | 6.034M |
| September 22, 2026 | 6.095M |
| September 21, 2026 | 6.217M |
| Date | Value |
|---|---|
| September 18, 2026 | 6.642M |
| September 17, 2026 | 6.977M |
| September 16, 2026 | 6.642M |
| September 15, 2026 | 6.703M |
| September 14, 2026 | 7.372M |
| September 11, 2026 | 7.737M |
| September 10, 2026 | 8.466M |
| September 09, 2026 | 8.649M |
| September 08, 2026 | 8.345M |
| September 04, 2026 | 8.953M |
| September 03, 2026 | 8.649M |
| September 02, 2026 | 9.804M |
| September 01, 2026 | 10.78M |
| August 31, 2026 | 8.406M |
| August 28, 2026 | 6.703M |
| August 27, 2026 | 7.007M |
| August 26, 2026 | 6.521M |
| August 25, 2026 | 6.460M |
| August 24, 2026 | 6.156M |
| August 21, 2026 | 6.703M |
| August 20, 2026 | 5.791M |
| August 19, 2026 | 5.183M |
| August 18, 2026 | 4.879M |
| August 17, 2026 | 4.149M |
| August 14, 2026 | 4.392M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ACADIA Pharmaceuticals, Inc. | 2.514B |
| Alnylam Pharmaceuticals, Inc. | 29.64B |
| Anika Therapeutics, Inc. | 273.50M |
| Savara, Inc. | 724.16M |
| Vericel Corp. | 2.108B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -4.117M |
| Total Expenses (Quarterly) | 4.117M |
| EPS Diluted (Quarterly) | -0.6564 |
| Earnings Yield | -593.7% |
| Normalized Earnings Yield | -556.25 |